Article

Key clinical point: Meta-analysis indicated a relatively higher but nonsignificantly increased risk for Helicobacter pylori infection (HPI) in patients with irritable bowel syndrome (IBS) vs non-IBS participants; however, the association between IBS and HPI could be an underestimation, with a positive association persisting between HPI and diarrhea-type IBS (IBS-D).

Major finding: A nonsignificant positive association was observed between HPI and IBS (odds ratio [OR], 1.03 ;lt; P = .84); however, the association was significant after excluding studies with defined confounding factors (adjusted OR, 1.29; P = .03), indicating an underestimation. The positive association of HPI persisted with IBS-D (OR, 1.54; P = .0003) but not with IBS-C (P = .17) or IBS-M (P = .33).

Study details: Findings are from a systematic review and meta-analysis of 13 studies including 1,403 patients with IBS and 11,770 non-IBS participants.

Disclosures: This research was funded by the National Natural Science Foundation of China and the Natural Science Foundation of Guangdong Province. The authors declared no conflicts of interest.

Source: Wang Z et al. Helicobacterpylori infection-A risk factor for irritable bowel syndrome? An updated systematic review and meta-analysis. Medicina (Kaunas). 2022;58(8):1035 (Aug 2). Doi: 10.3390/medicina58081035.

Key clinical point: Meta-analysis indicated a relatively higher but nonsignificantly increased risk for Helicobacter pylori infection (HPI) in patients with irritable bowel syndrome (IBS) vs non-IBS participants; however, the association between IBS and HPI could be an underestimation, with a positive association persisting between HPI and diarrhea-type IBS (IBS-D).

Major finding: A nonsignificant positive association was observed between HPI and IBS (odds ratio [OR], 1.03 ;lt; P = .84); however, the association was significant after excluding studies with defined confounding factors (adjusted OR, 1.29; P = .03), indicating an underestimation. The positive association of HPI persisted with IBS-D (OR, 1.54; P = .0003) but not with IBS-C (P = .17) or IBS-M (P = .33).

Study details: Findings are from a systematic review and meta-analysis of 13 studies including 1,403 patients with IBS and 11,770 non-IBS participants.

Disclosures: This research was funded by the National Natural Science Foundation of China and the Natural Science Foundation of Guangdong Province. The authors declared no conflicts of interest.

Source: Wang Z et al. Helicobacterpylori infection-A risk factor for irritable bowel syndrome? An updated systematic review and meta-analysis. Medicina (Kaunas). 2022;58(8):1035 (Aug 2). Doi: 10.3390/medicina58081035.

Key clinical point: Meta-analysis indicated a relatively higher but nonsignificantly increased risk for Helicobacter pylori infection (HPI) in patients with irritable bowel syndrome (IBS) vs non-IBS participants; however, the association between IBS and HPI could be an underestimation, with a positive association persisting between HPI and diarrhea-type IBS (IBS-D).

Major finding: A nonsignificant positive association was observed between HPI and IBS (odds ratio [OR], 1.03 ;lt; P = .84); however, the association was significant after excluding studies with defined confounding factors (adjusted OR, 1.29; P = .03), indicating an underestimation. The positive association of HPI persisted with IBS-D (OR, 1.54; P = .0003) but not with IBS-C (P = .17) or IBS-M (P = .33).

Study details: Findings are from a systematic review and meta-analysis of 13 studies including 1,403 patients with IBS and 11,770 non-IBS participants.

Disclosures: This research was funded by the National Natural Science Foundation of China and the Natural Science Foundation of Guangdong Province. The authors declared no conflicts of interest.

Source: Wang Z et al. Helicobacterpylori infection-A risk factor for irritable bowel syndrome? An updated systematic review and meta-analysis. Medicina (Kaunas). 2022;58(8):1035 (Aug 2). Doi: 10.3390/medicina58081035.

Key clinical point: Irritable bowel syndrome (IBS) is prevalent among veterans and is associated with significant psychological comorbidities.

Major finding: Overall, 28.4% of veterans met Rome IV IBS criteria, and significant associations of IBS with anxiety (adjusted odds ratio [aOR], 3.47; P < .001), depression (aOR, 2.88; P < .001), post-traumatic stress disorder (aOR, 3.09; P < .001), prior infectious enteritis (aOR, 4.44; P < .001), and a history of bowel problems after antibiotics (aOR, 1.84; P = .005) were observed.

Study details: The data come from a cross-sectional survey including 858 veteran respondents (mean age, 53.6 years), of whom 244 had IBS.

Disclosures: The authors declared no conflicts of interest.

Source: Shin A et al. The prevalence, humanistic burden, and healthcare impact of irritable bowel syndrome (IBS) among United States veterans. Clin Gastroenterol Hepatol. 2022 (Aug 11). Doi: 10.1016/j.cgh.2022.08.005.

Key clinical point: Irritable bowel syndrome (IBS) is prevalent among veterans and is associated with significant psychological comorbidities.

Major finding: Overall, 28.4% of veterans met Rome IV IBS criteria, and significant associations of IBS with anxiety (adjusted odds ratio [aOR], 3.47; P < .001), depression (aOR, 2.88; P < .001), post-traumatic stress disorder (aOR, 3.09; P < .001), prior infectious enteritis (aOR, 4.44; P < .001), and a history of bowel problems after antibiotics (aOR, 1.84; P = .005) were observed.

Study details: The data come from a cross-sectional survey including 858 veteran respondents (mean age, 53.6 years), of whom 244 had IBS.

Disclosures: The authors declared no conflicts of interest.

Source: Shin A et al. The prevalence, humanistic burden, and healthcare impact of irritable bowel syndrome (IBS) among United States veterans. Clin Gastroenterol Hepatol. 2022 (Aug 11). Doi: 10.1016/j.cgh.2022.08.005.

Key clinical point: Irritable bowel syndrome (IBS) is prevalent among veterans and is associated with significant psychological comorbidities.

Major finding: Overall, 28.4% of veterans met Rome IV IBS criteria, and significant associations of IBS with anxiety (adjusted odds ratio [aOR], 3.47; P < .001), depression (aOR, 2.88; P < .001), post-traumatic stress disorder (aOR, 3.09; P < .001), prior infectious enteritis (aOR, 4.44; P < .001), and a history of bowel problems after antibiotics (aOR, 1.84; P = .005) were observed.

Study details: The data come from a cross-sectional survey including 858 veteran respondents (mean age, 53.6 years), of whom 244 had IBS.

Disclosures: The authors declared no conflicts of interest.

Source: Shin A et al. The prevalence, humanistic burden, and healthcare impact of irritable bowel syndrome (IBS) among United States veterans. Clin Gastroenterol Hepatol. 2022 (Aug 11). Doi: 10.1016/j.cgh.2022.08.005.

Key clinical point: Somatization and celiac disease are the primary risk factors associated with irritable bowel syndrome (IBS) in both men and women.

Major finding: The risk for IBS was almost 4-fold higher in men (adjusted odds ratio [aOR] 4.786; 95% CI 4.544-5.041) and women (aOR 5.326; 95% CI 4.863-5.832) experiencing somatization, with the second important influencing factor being celiac disease (men: aOR 4.107; 95% CI 3.132-5.385; women: aOR 3.783; 95% CI 3.310-4.323).

Study details: This study included 31,918 participants who met the Rome III criteria for IBS and completed the Digestive Health Questionnaire.

Disclosures: This study was supported by QW of the National Natural Science Foundation of China and the National Office for Philosophy and Social Sciences. The authors declared no potential conflicts of interest.

Source: Wang K et al. Factors related to irritable bowel syndrome and differences among subtypes: A cross-sectional study in the UK Biobank. Front Pharmacol. 2022;13:905564 (Aug 26). Doi: 10.3389/fphar.2022.905564

Key clinical point: Somatization and celiac disease are the primary risk factors associated with irritable bowel syndrome (IBS) in both men and women.

Major finding: The risk for IBS was almost 4-fold higher in men (adjusted odds ratio [aOR] 4.786; 95% CI 4.544-5.041) and women (aOR 5.326; 95% CI 4.863-5.832) experiencing somatization, with the second important influencing factor being celiac disease (men: aOR 4.107; 95% CI 3.132-5.385; women: aOR 3.783; 95% CI 3.310-4.323).

Study details: This study included 31,918 participants who met the Rome III criteria for IBS and completed the Digestive Health Questionnaire.

Disclosures: This study was supported by QW of the National Natural Science Foundation of China and the National Office for Philosophy and Social Sciences. The authors declared no potential conflicts of interest.

Source: Wang K et al. Factors related to irritable bowel syndrome and differences among subtypes: A cross-sectional study in the UK Biobank. Front Pharmacol. 2022;13:905564 (Aug 26). Doi: 10.3389/fphar.2022.905564

Key clinical point: Somatization and celiac disease are the primary risk factors associated with irritable bowel syndrome (IBS) in both men and women.

Major finding: The risk for IBS was almost 4-fold higher in men (adjusted odds ratio [aOR] 4.786; 95% CI 4.544-5.041) and women (aOR 5.326; 95% CI 4.863-5.832) experiencing somatization, with the second important influencing factor being celiac disease (men: aOR 4.107; 95% CI 3.132-5.385; women: aOR 3.783; 95% CI 3.310-4.323).

Study details: This study included 31,918 participants who met the Rome III criteria for IBS and completed the Digestive Health Questionnaire.

Disclosures: This study was supported by QW of the National Natural Science Foundation of China and the National Office for Philosophy and Social Sciences. The authors declared no potential conflicts of interest.

Source: Wang K et al. Factors related to irritable bowel syndrome and differences among subtypes: A cross-sectional study in the UK Biobank. Front Pharmacol. 2022;13:905564 (Aug 26). Doi: 10.3389/fphar.2022.905564

Key clinical point: Supplementation with a multistrain probiotic for 30 days improved intestinal permeability, stool consistency, and health-related quality-of-life (QoL) in a considerable proportion of patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Major finding: On day 30, the intestinal permeability improved or normalized in 81.5% of patients, with the intestinal permeability decreasing by 3.4 units (P = .0005), the Bristol Stool Scale score decreasing by 0.9 units (P = .0057), and the IBS-QoL total score increasing by 8.0 points (95% CI 3.0-12.9). The multistrain probiotic was well tolerated.

Study details: The data come from a pilot, open-label, prospective, phase 4 study including 30 patients with IBS-D and leaky gut who received 2 capsules of multistrain probiotic daily for 30 days.

Disclosures: This study was sponsored by PiLeJe Laboratoire. SA Abdellah and C Gal declared being employees of PiLeJe Laboratoire. L Laterza and A Gasbarrini reported ties with various sources.

Source: Ait Abdellah S et al. Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): A pilot study. Dig Dis. 2022 (Aug 25). Doi: 10.1159/000526712

Key clinical point: Supplementation with a multistrain probiotic for 30 days improved intestinal permeability, stool consistency, and health-related quality-of-life (QoL) in a considerable proportion of patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Major finding: On day 30, the intestinal permeability improved or normalized in 81.5% of patients, with the intestinal permeability decreasing by 3.4 units (P = .0005), the Bristol Stool Scale score decreasing by 0.9 units (P = .0057), and the IBS-QoL total score increasing by 8.0 points (95% CI 3.0-12.9). The multistrain probiotic was well tolerated.

Study details: The data come from a pilot, open-label, prospective, phase 4 study including 30 patients with IBS-D and leaky gut who received 2 capsules of multistrain probiotic daily for 30 days.

Disclosures: This study was sponsored by PiLeJe Laboratoire. SA Abdellah and C Gal declared being employees of PiLeJe Laboratoire. L Laterza and A Gasbarrini reported ties with various sources.

Source: Ait Abdellah S et al. Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): A pilot study. Dig Dis. 2022 (Aug 25). Doi: 10.1159/000526712

Key clinical point: Supplementation with a multistrain probiotic for 30 days improved intestinal permeability, stool consistency, and health-related quality-of-life (QoL) in a considerable proportion of patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Major finding: On day 30, the intestinal permeability improved or normalized in 81.5% of patients, with the intestinal permeability decreasing by 3.4 units (P = .0005), the Bristol Stool Scale score decreasing by 0.9 units (P = .0057), and the IBS-QoL total score increasing by 8.0 points (95% CI 3.0-12.9). The multistrain probiotic was well tolerated.

Study details: The data come from a pilot, open-label, prospective, phase 4 study including 30 patients with IBS-D and leaky gut who received 2 capsules of multistrain probiotic daily for 30 days.

Disclosures: This study was sponsored by PiLeJe Laboratoire. SA Abdellah and C Gal declared being employees of PiLeJe Laboratoire. L Laterza and A Gasbarrini reported ties with various sources.

Source: Ait Abdellah S et al. Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): A pilot study. Dig Dis. 2022 (Aug 25). Doi: 10.1159/000526712

Key clinical point: Endometriosis is associated with a 3-fold increase in the risk for irritable bowel syndrome (IBS), with 1 in every 5 women with endometriosis having IBS.

Major finding: The odds of IBS were significantly higher in women with endometriosis compared with healthy controls (odds ratio 2.97; 95% CI 2.17-4.06), and the pooled prevalence of IBS among women with endometriosis was 23.4% (95% CI 9.7%-37.2%).

Study details: This study evaluated the prevalence of IBS in endometriosis (meta-analysis of 6 studies) and association between endometriosis and IBS (meta-analysis of 11 studies involving 18,887 patients with endometriosis and 77,171 healthy controls).

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Nabi MY et al. Endometriosis and irritable bowel syndrome: A systematic review and meta-analyses. Front Med (Lausanne). 2022;9:914356 (Jul 25). Doi: 10.3389/fmed.2022.914356

Key clinical point: Endometriosis is associated with a 3-fold increase in the risk for irritable bowel syndrome (IBS), with 1 in every 5 women with endometriosis having IBS.

Major finding: The odds of IBS were significantly higher in women with endometriosis compared with healthy controls (odds ratio 2.97; 95% CI 2.17-4.06), and the pooled prevalence of IBS among women with endometriosis was 23.4% (95% CI 9.7%-37.2%).

Study details: This study evaluated the prevalence of IBS in endometriosis (meta-analysis of 6 studies) and association between endometriosis and IBS (meta-analysis of 11 studies involving 18,887 patients with endometriosis and 77,171 healthy controls).

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Nabi MY et al. Endometriosis and irritable bowel syndrome: A systematic review and meta-analyses. Front Med (Lausanne). 2022;9:914356 (Jul 25). Doi: 10.3389/fmed.2022.914356

Key clinical point: Endometriosis is associated with a 3-fold increase in the risk for irritable bowel syndrome (IBS), with 1 in every 5 women with endometriosis having IBS.

Major finding: The odds of IBS were significantly higher in women with endometriosis compared with healthy controls (odds ratio 2.97; 95% CI 2.17-4.06), and the pooled prevalence of IBS among women with endometriosis was 23.4% (95% CI 9.7%-37.2%).

Study details: This study evaluated the prevalence of IBS in endometriosis (meta-analysis of 6 studies) and association between endometriosis and IBS (meta-analysis of 11 studies involving 18,887 patients with endometriosis and 77,171 healthy controls).

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Nabi MY et al. Endometriosis and irritable bowel syndrome: A systematic review and meta-analyses. Front Med (Lausanne). 2022;9:914356 (Jul 25). Doi: 10.3389/fmed.2022.914356

Key clinical point: More than two-thirds of patients with inflammatory bowel disease (IBD) were affected by irritable bowel syndrome (IBS)-type symptoms, which were associated with worse depression, anxiety, somatoform symptoms, and quality-of-life scores.

Major finding: Overall, 67.2% of patients reported IBS-type symptoms at least once during the follow-up, with anxiety, depression, and somatoform symptom scores being worse in patients with vs without IBS-type symptoms (P < .001).

Study details: The data come from a 6-year longitudinal follow-up study including 760 individuals with well-characterized IBD.

Disclosures: This study was funded by The Leeds Teaching Hospitals Charitable Foundation and Tillotts Pharma U.K. Ltd. The authors declared no conflicts of interest.

Source: Fairbrass KM et al. Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up. Aliment Pharmacol Ther. 2022 (Aug 22). Doi: 10.1111/apt.17193

Key clinical point: More than two-thirds of patients with inflammatory bowel disease (IBD) were affected by irritable bowel syndrome (IBS)-type symptoms, which were associated with worse depression, anxiety, somatoform symptoms, and quality-of-life scores.

Major finding: Overall, 67.2% of patients reported IBS-type symptoms at least once during the follow-up, with anxiety, depression, and somatoform symptom scores being worse in patients with vs without IBS-type symptoms (P < .001).

Study details: The data come from a 6-year longitudinal follow-up study including 760 individuals with well-characterized IBD.

Disclosures: This study was funded by The Leeds Teaching Hospitals Charitable Foundation and Tillotts Pharma U.K. Ltd. The authors declared no conflicts of interest.

Source: Fairbrass KM et al. Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up. Aliment Pharmacol Ther. 2022 (Aug 22). Doi: 10.1111/apt.17193

Key clinical point: More than two-thirds of patients with inflammatory bowel disease (IBD) were affected by irritable bowel syndrome (IBS)-type symptoms, which were associated with worse depression, anxiety, somatoform symptoms, and quality-of-life scores.

Major finding: Overall, 67.2% of patients reported IBS-type symptoms at least once during the follow-up, with anxiety, depression, and somatoform symptom scores being worse in patients with vs without IBS-type symptoms (P < .001).

Study details: The data come from a 6-year longitudinal follow-up study including 760 individuals with well-characterized IBD.

Disclosures: This study was funded by The Leeds Teaching Hospitals Charitable Foundation and Tillotts Pharma U.K. Ltd. The authors declared no conflicts of interest.

Source: Fairbrass KM et al. Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up. Aliment Pharmacol Ther. 2022 (Aug 22). Doi: 10.1111/apt.17193

Key clinical point: The risk for incident irritable bowel syndrome (IBS) was significantly higher in individuals in the highest vs lowest quartile of nonalcoholic fatty liver index and in those with a diagnosis of nonalcoholic fatty liver disease (NAFLD).

Major finding: The risk of developing IBS was 21% higher among individuals in the highest vs lowest quartile of fatty liver index (hazard ratio [HR] 1.21; P_trend < .001) and 13% higher among patients with vs without NAFLD (HR 1.13; 95% CI 1.05-1.17).

Study details: Findings are from an analysis of 396,838 participants from a large-scale prospective cohort who were free from IBS, any cancer, inflammatory bowel disease, alcoholic liver disease, and celiac disease, of which 38.6% had an NAFLD diagnosis.

Disclosures: This study was funded by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Wu S et al. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: A prospective cohort study. BMC Med. 2022;20(1):262 (Aug 22). Doi: 10.1186/s12916-022-02460-8

Key clinical point: The risk for incident irritable bowel syndrome (IBS) was significantly higher in individuals in the highest vs lowest quartile of nonalcoholic fatty liver index and in those with a diagnosis of nonalcoholic fatty liver disease (NAFLD).

Major finding: The risk of developing IBS was 21% higher among individuals in the highest vs lowest quartile of fatty liver index (hazard ratio [HR] 1.21; P_trend < .001) and 13% higher among patients with vs without NAFLD (HR 1.13; 95% CI 1.05-1.17).

Study details: Findings are from an analysis of 396,838 participants from a large-scale prospective cohort who were free from IBS, any cancer, inflammatory bowel disease, alcoholic liver disease, and celiac disease, of which 38.6% had an NAFLD diagnosis.

Disclosures: This study was funded by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Wu S et al. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: A prospective cohort study. BMC Med. 2022;20(1):262 (Aug 22). Doi: 10.1186/s12916-022-02460-8

Key clinical point: The risk for incident irritable bowel syndrome (IBS) was significantly higher in individuals in the highest vs lowest quartile of nonalcoholic fatty liver index and in those with a diagnosis of nonalcoholic fatty liver disease (NAFLD).

Major finding: The risk of developing IBS was 21% higher among individuals in the highest vs lowest quartile of fatty liver index (hazard ratio [HR] 1.21; P_trend < .001) and 13% higher among patients with vs without NAFLD (HR 1.13; 95% CI 1.05-1.17).

Study details: Findings are from an analysis of 396,838 participants from a large-scale prospective cohort who were free from IBS, any cancer, inflammatory bowel disease, alcoholic liver disease, and celiac disease, of which 38.6% had an NAFLD diagnosis.

Disclosures: This study was funded by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Wu S et al. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: A prospective cohort study. BMC Med. 2022;20(1):262 (Aug 22). Doi: 10.1186/s12916-022-02460-8

Key clinical point: Once-daily 75 mg vibegron was not associated with a clinically significant improvement in irritable bowel syndrome (IBS)-associated abdominal pain in women with diarrhea-predominant IBS (IBS-D) or mixed diarrhea/constipation IBS (IBS-M).

Major finding: At week 12, the percentage of women with IBS-D (40.9% vs 42.9%; P = .8222) or IBS-M (28.9% vs 24.4%; P = .6151) experiencing ≥30% improvement in IBS-associated abdominal pain was not significantly different with vibegron vs placebo. The incidence of treatment-emergent adverse events was comparable between the treatment groups.

Study details: The data come from a phase 2 randomized controlled trial including 222 adult women with IBS-D or IBS-M who were randomly assigned to receive 75 mg vibegron (n = 111) or placebo (n = 111).

Disclosures: This study was funded by Urovant Sciences. J King, D Shortino, C Schaumburg, and C Haag-Molkenteller declared being former employees of Urovant Sciences. Some authors declared receiving research grants or serving as consultants or on scientific advisory boards for various sources, including Urovant Sciences.

Source: Lacy BE et al. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial. Neurogastroenterol Motil. 2022;e14448 (Aug 16). Doi: 10.1111/nmo.14448

Key clinical point: Once-daily 75 mg vibegron was not associated with a clinically significant improvement in irritable bowel syndrome (IBS)-associated abdominal pain in women with diarrhea-predominant IBS (IBS-D) or mixed diarrhea/constipation IBS (IBS-M).

Major finding: At week 12, the percentage of women with IBS-D (40.9% vs 42.9%; P = .8222) or IBS-M (28.9% vs 24.4%; P = .6151) experiencing ≥30% improvement in IBS-associated abdominal pain was not significantly different with vibegron vs placebo. The incidence of treatment-emergent adverse events was comparable between the treatment groups.

Study details: The data come from a phase 2 randomized controlled trial including 222 adult women with IBS-D or IBS-M who were randomly assigned to receive 75 mg vibegron (n = 111) or placebo (n = 111).

Disclosures: This study was funded by Urovant Sciences. J King, D Shortino, C Schaumburg, and C Haag-Molkenteller declared being former employees of Urovant Sciences. Some authors declared receiving research grants or serving as consultants or on scientific advisory boards for various sources, including Urovant Sciences.

Source: Lacy BE et al. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial. Neurogastroenterol Motil. 2022;e14448 (Aug 16). Doi: 10.1111/nmo.14448

Key clinical point: Once-daily 75 mg vibegron was not associated with a clinically significant improvement in irritable bowel syndrome (IBS)-associated abdominal pain in women with diarrhea-predominant IBS (IBS-D) or mixed diarrhea/constipation IBS (IBS-M).

Major finding: At week 12, the percentage of women with IBS-D (40.9% vs 42.9%; P = .8222) or IBS-M (28.9% vs 24.4%; P = .6151) experiencing ≥30% improvement in IBS-associated abdominal pain was not significantly different with vibegron vs placebo. The incidence of treatment-emergent adverse events was comparable between the treatment groups.

Study details: The data come from a phase 2 randomized controlled trial including 222 adult women with IBS-D or IBS-M who were randomly assigned to receive 75 mg vibegron (n = 111) or placebo (n = 111).

Disclosures: This study was funded by Urovant Sciences. J King, D Shortino, C Schaumburg, and C Haag-Molkenteller declared being former employees of Urovant Sciences. Some authors declared receiving research grants or serving as consultants or on scientific advisory boards for various sources, including Urovant Sciences.

Source: Lacy BE et al. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial. Neurogastroenterol Motil. 2022;e14448 (Aug 16). Doi: 10.1111/nmo.14448

Key clinical point: An 8-week treatment with mesalazine offered no clear benefits over placebo for global improvement of irritable bowel syndrome (IBS) symptoms.

Major finding: A similar proportion of patients receiving mesalazine vs placebo reported satisfactory relief of IBS symptoms during ≥50% of the treatment weeks (36% vs 30%; P = .40); however, the improvement in abdominal bloating was significantly greater in the mesalazine vs placebo group (P = .02).

Study details: The data come from a randomized controlled trial including 181 patients with IBS who were assigned to an 8-week treatment with 2400 mg mesalazine orally or placebo once daily.

Disclosures: This study was funded by Eurostars project grant from Tillotts Pharma AB and by the Swedish state. Some authors declared receiving research grants or serving as consultants or on advisory boards for various sources, including Tillotts Pharma.

Source: Tejera VC et al. Randomised clinical trial and meta-analysis: Mesalazine treatment in irritable bowel syndrome—Effects on gastrointestinal symptoms and rectal biomarkers of immune activity. Aliment Pharmacol Ther. 2022;56(6):968-979 (Aug 8). Doi: 10.1111/apt.17182

Key clinical point: An 8-week treatment with mesalazine offered no clear benefits over placebo for global improvement of irritable bowel syndrome (IBS) symptoms.

Major finding: A similar proportion of patients receiving mesalazine vs placebo reported satisfactory relief of IBS symptoms during ≥50% of the treatment weeks (36% vs 30%; P = .40); however, the improvement in abdominal bloating was significantly greater in the mesalazine vs placebo group (P = .02).

Study details: The data come from a randomized controlled trial including 181 patients with IBS who were assigned to an 8-week treatment with 2400 mg mesalazine orally or placebo once daily.

Disclosures: This study was funded by Eurostars project grant from Tillotts Pharma AB and by the Swedish state. Some authors declared receiving research grants or serving as consultants or on advisory boards for various sources, including Tillotts Pharma.

Source: Tejera VC et al. Randomised clinical trial and meta-analysis: Mesalazine treatment in irritable bowel syndrome—Effects on gastrointestinal symptoms and rectal biomarkers of immune activity. Aliment Pharmacol Ther. 2022;56(6):968-979 (Aug 8). Doi: 10.1111/apt.17182

Key clinical point: An 8-week treatment with mesalazine offered no clear benefits over placebo for global improvement of irritable bowel syndrome (IBS) symptoms.

Major finding: A similar proportion of patients receiving mesalazine vs placebo reported satisfactory relief of IBS symptoms during ≥50% of the treatment weeks (36% vs 30%; P = .40); however, the improvement in abdominal bloating was significantly greater in the mesalazine vs placebo group (P = .02).

Study details: The data come from a randomized controlled trial including 181 patients with IBS who were assigned to an 8-week treatment with 2400 mg mesalazine orally or placebo once daily.

Disclosures: This study was funded by Eurostars project grant from Tillotts Pharma AB and by the Swedish state. Some authors declared receiving research grants or serving as consultants or on advisory boards for various sources, including Tillotts Pharma.

Source: Tejera VC et al. Randomised clinical trial and meta-analysis: Mesalazine treatment in irritable bowel syndrome—Effects on gastrointestinal symptoms and rectal biomarkers of immune activity. Aliment Pharmacol Ther. 2022;56(6):968-979 (Aug 8). Doi: 10.1111/apt.17182

Key clinical point: The use of probiotic supplementation reduced disease severity in adult patients with atopic dermatitis (AD).

Major finding: Probiotic supplementation vs placebo led to a significant reduction in the Scoring AD index (mean difference −7.90; 95% CI −7.25 to−6.92), but no significant improvements in skin severity and itch severity.

Study details: Findings are from a meta-analysis of six randomized controlled trials including 241 adults with AD, of which 128 received probiotics and 113 received placebo.

Disclosures: This study was funded by a grant from Universitas Airlangga, Indonesia. The authors declared no conflicts of interest.

Source: Umborowati MA et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. J Health Popul Nutr. 2022;41:37 (Aug 17). Doi: 10.1186/s41043-022-00318-6

Key clinical point: The use of probiotic supplementation reduced disease severity in adult patients with atopic dermatitis (AD).

Major finding: Probiotic supplementation vs placebo led to a significant reduction in the Scoring AD index (mean difference −7.90; 95% CI −7.25 to−6.92), but no significant improvements in skin severity and itch severity.

Study details: Findings are from a meta-analysis of six randomized controlled trials including 241 adults with AD, of which 128 received probiotics and 113 received placebo.

Disclosures: This study was funded by a grant from Universitas Airlangga, Indonesia. The authors declared no conflicts of interest.

Source: Umborowati MA et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. J Health Popul Nutr. 2022;41:37 (Aug 17). Doi: 10.1186/s41043-022-00318-6

Key clinical point: The use of probiotic supplementation reduced disease severity in adult patients with atopic dermatitis (AD).

Major finding: Probiotic supplementation vs placebo led to a significant reduction in the Scoring AD index (mean difference −7.90; 95% CI −7.25 to−6.92), but no significant improvements in skin severity and itch severity.

Study details: Findings are from a meta-analysis of six randomized controlled trials including 241 adults with AD, of which 128 received probiotics and 113 received placebo.

Disclosures: This study was funded by a grant from Universitas Airlangga, Indonesia. The authors declared no conflicts of interest.

Source: Umborowati MA et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. J Health Popul Nutr. 2022;41:37 (Aug 17). Doi: 10.1186/s41043-022-00318-6